Neurotoxicity of cisplatin +/- reduced glutathione in the first-line treatment of advanced ovarian cancer

International Journal of Gynecological Cancer

Volumn 6, Issue 5, 1996, Pages 415-419

  Bogliun, G ^a   Marzorati, L ^a   Marzola, M ^a   Miceli, M D ^a   Cantu M G ^a   Cavaletti, G ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

Author keywords

cisplatin; glutathione; neuroprotection; toxicity

Indexed keywords

CISPLATIN; GLUCOSE; GLUTATHIONE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEUROLOGIC EXAMINATION; NEUROPROTECTION; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL;

EID: 0029775775     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1996.06050415.x     Document Type: Article

References (16)

1. Mollman JE. Cisplatin neurotoxicity. N Engl J Med 1990; 322: 126-7.
2. Caveletti G, Marzorati L, Bogliun G, et al. Cisplatin-induced peripheral neurotoxicity is dependent on total dose intensity and single dose intensity. Cancer 1992; 1: 203-7.
3. Gandara DR, Perez EA, Wiebe V, De Gregorio MW. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity. Sem Oncol 1991; 18 (Suppl 3): 49-55.
4. Alberts DS, Noel JK. Cisplatin-associated neurotoxicity: can it be prevented? Anti-Cancer Drugs 1995; 6: 369-83.
5. Tredici G, Cavaletti G, Petruccioli MG, Fabbrica D, Tedeschi M, Venturino P. Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats. Neuro Toxicol 1994; 15: 701-4.
6. Cavaletti G, Minoia C, Schieppati M, Tredici G. Protective effect of glutathione on cisplatin neurotoxicity in rats. Int J Radiat Oncol Biol Phys 1994; 29: 771-6.
7. Di Re F, Bohm S, Oriana S, Spatti GB, Zunino F. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer. Cancer Chemother Pharmacol 1990; 25: 355-60.
8. Colombo N, Bini S, Miceli D, et al. Weekly cisplatin +/-glutathione in relapsed ovarian carcinoma. Int J Gynecol Cancer 1995; 5: 81-6.
9. Report presented by the Cancer Committee to the General aaasmbly of FIGO: New York, April 1970. Int J Gynecol Obstet 1971; 9: 172-80.
10. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the ECOG. Am J Clin Oncol 1982; 5: 649-55.
11. WHO. WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization, Geneva, Switzerland, 1979.
12. Dyck PJ, Sherman WR, Halker LM, et al. Human diabetic endoneural sorbitol, fructose and myo-inositol related to sural nerve morphometry. Ann Neurol 1980; 8: 590-6.
13. Smyth JF, Perren T, Wilkinson P, Prescott RJ, Quinn KJ, Tedeschi M. Cisplatin (CP) ± glutathione (GSH): a randomised study in stage I-IV ovarian cancer. Proceedings of the 19th Congress of the European Society for Medical Oncology Lisbon: 1994.
14. Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 1995; 13: 26-32.
15. Bogliun G, Marzorati L, Cavaletti G. Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione. Ital J Neurol Sci 1992; 13: 643-7.
16. Hamers FPT, Brakkee JH, Cavalletti E, et al. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res 1993; 53: 544-9.